Molecular pathology data for patients with PCA and typical Alzheimer’s disease
| Diagnosis . | Amyloid 18 F imaging . | CSF total tau pg/ml . | CSF amyoid-β1-42 pg/ml . | CSF tau:amyloid-β ratio . | Interpretation . |
|---|---|---|---|---|---|
| PCA | Not available | 310 | 488 | 0.64 | − |
| PCA | Not available | 931 | 625 | 1.49 | + |
| PCA | positive | 1072 | 126 | 8.51 | ++ |
| PCA | Not available | 151 | 147 | 1.03 | + |
| PCA | positive | Not available | Not available | Not available | ++ |
| PCA | positive | 1082 | 365 | 2.96 | ++ |
| PCA | positive | Not available | Not available | Not available | ++ |
| tAD | Not available | 289 | 280 | 1.03 | + |
| tAD | Not available | 757 | 285 | 2.66 | ++ |
| tAD | Not available | 940 | 348 | 2.70 | ++ |
| tAD | Not available | 952 | 195 | 4.88 | ++ |
| tAD | Not available | 977 | 322 | 3.03 | ++ |
| tAD | Not available | 625 | 277 | 2.26 | ++ |
| tAD | Not available | >1200 | 313 | >3.83 | ++ |
| tAD | Not available | 913 | 191 | 4.78 | ++ |
| tAD | Not available | >1200 | 217 | >5.52 | ++ |
| tAD | Not available | 1099 | 195 | 5.64 | ++ |
| tAD | Not available | 850 | 362 | 2.35 | ++ |
| Diagnosis . | Amyloid 18 F imaging . | CSF total tau pg/ml . | CSF amyoid-β1-42 pg/ml . | CSF tau:amyloid-β ratio . | Interpretation . |
|---|---|---|---|---|---|
| PCA | Not available | 310 | 488 | 0.64 | − |
| PCA | Not available | 931 | 625 | 1.49 | + |
| PCA | positive | 1072 | 126 | 8.51 | ++ |
| PCA | Not available | 151 | 147 | 1.03 | + |
| PCA | positive | Not available | Not available | Not available | ++ |
| PCA | positive | 1082 | 365 | 2.96 | ++ |
| PCA | positive | Not available | Not available | Not available | ++ |
| tAD | Not available | 289 | 280 | 1.03 | + |
| tAD | Not available | 757 | 285 | 2.66 | ++ |
| tAD | Not available | 940 | 348 | 2.70 | ++ |
| tAD | Not available | 952 | 195 | 4.88 | ++ |
| tAD | Not available | 977 | 322 | 3.03 | ++ |
| tAD | Not available | 625 | 277 | 2.26 | ++ |
| tAD | Not available | >1200 | 313 | >3.83 | ++ |
| tAD | Not available | 913 | 191 | 4.78 | ++ |
| tAD | Not available | >1200 | 217 | >5.52 | ++ |
| tAD | Not available | 1099 | 195 | 5.64 | ++ |
| tAD | Not available | 850 | 362 | 2.35 | ++ |
tAD = typical Alzheimer’s disease.
Where results do not support Alzheimer’s disease pathology (−), are borderline consistent with Alzheimer’s disease pathology (+) and are >85% specific for Alzheimer’s disease pathology (++). Amyloid (florbetapir) PET scans were received as part of another investigation.
Molecular pathology data for patients with PCA and typical Alzheimer’s disease
| Diagnosis . | Amyloid 18 F imaging . | CSF total tau pg/ml . | CSF amyoid-β1-42 pg/ml . | CSF tau:amyloid-β ratio . | Interpretation . |
|---|---|---|---|---|---|
| PCA | Not available | 310 | 488 | 0.64 | − |
| PCA | Not available | 931 | 625 | 1.49 | + |
| PCA | positive | 1072 | 126 | 8.51 | ++ |
| PCA | Not available | 151 | 147 | 1.03 | + |
| PCA | positive | Not available | Not available | Not available | ++ |
| PCA | positive | 1082 | 365 | 2.96 | ++ |
| PCA | positive | Not available | Not available | Not available | ++ |
| tAD | Not available | 289 | 280 | 1.03 | + |
| tAD | Not available | 757 | 285 | 2.66 | ++ |
| tAD | Not available | 940 | 348 | 2.70 | ++ |
| tAD | Not available | 952 | 195 | 4.88 | ++ |
| tAD | Not available | 977 | 322 | 3.03 | ++ |
| tAD | Not available | 625 | 277 | 2.26 | ++ |
| tAD | Not available | >1200 | 313 | >3.83 | ++ |
| tAD | Not available | 913 | 191 | 4.78 | ++ |
| tAD | Not available | >1200 | 217 | >5.52 | ++ |
| tAD | Not available | 1099 | 195 | 5.64 | ++ |
| tAD | Not available | 850 | 362 | 2.35 | ++ |
| Diagnosis . | Amyloid 18 F imaging . | CSF total tau pg/ml . | CSF amyoid-β1-42 pg/ml . | CSF tau:amyloid-β ratio . | Interpretation . |
|---|---|---|---|---|---|
| PCA | Not available | 310 | 488 | 0.64 | − |
| PCA | Not available | 931 | 625 | 1.49 | + |
| PCA | positive | 1072 | 126 | 8.51 | ++ |
| PCA | Not available | 151 | 147 | 1.03 | + |
| PCA | positive | Not available | Not available | Not available | ++ |
| PCA | positive | 1082 | 365 | 2.96 | ++ |
| PCA | positive | Not available | Not available | Not available | ++ |
| tAD | Not available | 289 | 280 | 1.03 | + |
| tAD | Not available | 757 | 285 | 2.66 | ++ |
| tAD | Not available | 940 | 348 | 2.70 | ++ |
| tAD | Not available | 952 | 195 | 4.88 | ++ |
| tAD | Not available | 977 | 322 | 3.03 | ++ |
| tAD | Not available | 625 | 277 | 2.26 | ++ |
| tAD | Not available | >1200 | 313 | >3.83 | ++ |
| tAD | Not available | 913 | 191 | 4.78 | ++ |
| tAD | Not available | >1200 | 217 | >5.52 | ++ |
| tAD | Not available | 1099 | 195 | 5.64 | ++ |
| tAD | Not available | 850 | 362 | 2.35 | ++ |
tAD = typical Alzheimer’s disease.
Where results do not support Alzheimer’s disease pathology (−), are borderline consistent with Alzheimer’s disease pathology (+) and are >85% specific for Alzheimer’s disease pathology (++). Amyloid (florbetapir) PET scans were received as part of another investigation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
